Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

of subcutaneous Keytruda given alone in relapsed or refractory classical Hodgkin lymphoma and relapsed or refractory primary mediastinal large B-cell lymphoma. Another phase 2 trial will gauge ...

Seagen has a long history in ADC development, claiming FDA approval for Adcetris (brentuximab vedotin) as a treatment for classical Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

This lawsuit, commenced in June 2019, centers on allegations that Roundup and other glyphosate-based herbicides cause Non-Hodgkin's Lymphoma ("NHL"), (a type of cancer) and that the Defendants failed ...

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving ...

Seven oral presentations will unveil novel immunotherapy insights, including IBI363, at one of oncology’s biggest global ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

In January 2023, Hendriks announced that he had been diagnosed with non-Hodgkin lymphoma and was undergoing treatment ahead of the MLB season. He underwent his last chemotherapy treatment that ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...